The faculty of the Department of Neurological Surgery at Northwestern University Feinberg School of Medicine believe that research plays a critical role in the advancement of care. Learn more about the innovative research projects in each of our medical specialties.
My research is directed towards elucidating the molecular and biological consequences of specific gene alterations in CNS cancer, with particular emphasis on malignant glioma, the most common type of primary CNS tumor, and towards identifying actionable/druggable molecular characteristics of these tumors.
My laboratory focuses on the the development of biological therapies for primary and metastatic brain cancer. We focus on immunotherapy, stem cell biology, gene therapy, and nanotechnology applications to brain tumors. Our goal is to uncover pathways which can be targeted with selected agents and my laboratory closely works with the NIH and the FDA to develop novel therapies for patients with brain cancer. For more information, please see www.lesniaklab.com.
Our lab studies the biology of pediatric brain tumors to identify and test novel molecular targets for more effective therapies. Our overarching research goal is to identify biomarkers of disease and develop new therapeutic strategies to improve clinical outcomes for children with brain tumors.
My research utilizes DNA sequencing, gene expression profiling, proteomic analyses, flow cytometric methodology and many other basic techniques to pursue goals that are ultimately translatable for improving health and overall survival in patients with brain cancer such as malignant glioma, with a special emphasis on glioblastoma. We are also interested in pursuing incurable pediatric brain tumors, as well as metastatic tumors that invade the brain/spinal cord.
My research focuses on precision medicine and its application for brain tumors. I am is focused on the use of molecular analysis to personalize treatments for patients with malignant brain tumors and the delivery of these treatments directly into the brain to improve their efficacy while avoiding unnecessary side effects. Learn more about our publications and research at the Adam Sonabend Lab website.
My primary research interest lies in identifying new effective therapies to improve the outcome of children with brain cancer. We develop and utilize patient-derived brain tumor model for preclinical testing of new therapeutic agents as well as new drug delivery system bypassing the blood-brain barrier. Our current focus has been to study novel epigenetic therapies that will interact with conventional genotoxic therapeutics targeting the unique molecular abnormalities present in pediatric brain cancer.
Learn more about our most recent publications and research at the Hashizume Laboratory website.
My translational work focuses on the effects of altered glioma metabolism in the microenvironment. Mutations in isocitrate dehydrogenase 1 or 2 (mutant IDH1/2) are present in a large proportion of gliomas, and are known to alter tumor metabolism and DNA methylation. For more information, please visit our webpage. Additionally, I serve as the Director of the Nervous System Tumor Bank (NSTB) for the Northwestern Brain Tumor Institute. The NSTB provides all NBTI researchers with patient-derived biospecimens and neuropathological support.
The Balyasnikova Lab is dedicated to the advancement and development of translational, cell-based targeted therapy for the treatment of glioblastoma and other brain malignancies. We also aim to develop imaging techniques for the tracking of stem cells in the central nervous system, improving our understanding of therapeutic mechanisms. Finally, as we look towards the future of brain cancer treatment, we are committed to the training of aspiring research professionals.
For more information, please visit the Balyasnikova Lab webpage.
The Ahmed Laboratory focuses on understanding the evaluation of therapeutic resistance in brain cancer.
The lab uses a combination of stem and cancer cell biology, advance molecular biology techniques (such as DNA chip technology, Next-Gen Sequencing, Chip-seq analysis, transgenic animal models and patient-derived orthotopic brain tumor animal models) and advanced in vivo imaging techniques to understand the molecular mechanism of therapeutic resistance and disease recurrence in brain tumors.
The main focus of this laboratory research is to:
1. Investigate the role of cellular and epigenetic plasticity in brain tumor recurrence
2. Advance the understanding of the Cancer Stem Cell Theory
3. Develop effective targeted therapy to prevent brain tumor recurrence
For more information please visit the Ahmed Laboratory webpage.